Kawada S, Chakraborty P, Roche L, et al. - Given that a high risk for developing atrial tachyarrhythmias (AAs) has been seen in patients with Fontan circulation, therefore, researchers assessed the efficacy as well as the safety of amiodarone in the treatment of ATs in adult Fontan patients, in this single-centre, retrospective study. Participants were 61 patients (mean age 31.6±11.3 years, 40.9% female), who received amiodarone between 1995 and 2018. At 1, 3 and 5 years, AAs free survival were estimated to be 76.2%, 56.9% and 30.6%, respectively. According to findings, amiodarone displayed acceptable short-term efficacy in Fontan physiology, however, long-term use was shown to be related to a decrease of efficacy and a significant prevalence of non-cardiac side effects. Exacerbation of heart failure was observed in relation to amiodarone-induced thyrotoxicosis. Consideration should be given to judicious use of amiodarone in this population.